China Medical System Holdings Limited (CMS) reported to the Hong Kong Stock Exchange that it repurchased 0.90 million ordinary shares on 3 June 2026, deploying HK$9.69 million of cash at prices ranging from HK$10.62 to HK$11.00 per share, with a volume-weighted average cost of HK$10.76.

Following the transaction, the company’s issued share base (excluding treasury shares) decreased by 0.04 % to 2.44 billion shares, while treasury holdings increased from 2.18 million to 3.08 million shares. Total issued shares remain unchanged at 2.44 billion.

The buyback forms part of the mandate authorised on 23 April 2026, which permits the repurchase of up to 243.95 million shares. Cumulative repurchases under this mandate now stand at 3.08 million shares, equivalent to 0.13 % of the company’s issued share capital on the mandate date.

In line with Hong Kong listing rules, CMS is subject to a moratorium on new share issues or treasury share disposals until 3 July 2026. The company confirmed that the repurchase complied with all relevant regulations and internal approvals.